Epidiolex: payments to doctors
Payments that named Epidiolex as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $8.9M
- Providers
- 9,026
- Transactions
- 53,504
- Average per transaction
- $166
The per-transaction average — $166 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9,026 providers the average total is $982, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| JAZZ Pharmaceuticals Inc. | $5,271,034 | 59.4% |
| Greenwich Biosciences, Inc. | $2,760,434 | 31.1% |
| Jazz Pharmaceuticals Inc. | $422,554 | 4.8% |
| GW Research Limited | $342,373 | 3.9% |
| GW Pharma Limited | $70,941 | 0.8% |